Target Name: MIR127
NCBI ID: G406914
Review Report on MIR127 Target / Biomarker Content of Review Report on MIR127 Target / Biomarker
MIR127
Other Name(s): mir-127 | MIRN127 | hsa-miR-127-3p | hsa-miR-127-5p | miRNA127 | hsa-mir-127 | MicroRNA 127 | microRNA 127

MIR127: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

MIR127, also known as mir-127, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. MIR127 is a small non-coding RNA molecule that plays a critical role in regulating gene expression in various organisms, including humans. It is composed of 197 amino acid residues and has a unique structure that is composed of a long stem-loop and a short terminal region.

MIR127 is a highly conserved gene that is expressed in various tissues and organs, including the brain, heart, and gastrointestinal tract. It is also expressed in various types of cancer, including breast, lung, and ovarian cancer. MIR127 has been shown to be involved in various cellular processes, including cell growth, apoptosis, and inflammation.

One of the reasons why MIR127 has potential as a drug target is its involvement in the regulation of cell apoptosis, which is the process by which cells die when they have reached their maximum number of copies and are no longer needed. MIR127 has been shown to play a role in the regulation of apoptosis by activating the B-cell lymphoma 1 (Bcl-2) gene. Bcl-2 is a tumor suppressor gene that has been shown to prevent apoptosis and promote cell survival. By activating Bcl-2, MIR127 has been shown to promote the survival of cancer cells, making it a potential drug target.

Another reason why MIR127 has potential as a drug target is its involvement in the regulation of cell signaling pathways. MIR127 has been shown to play a role in the regulation of several signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway. TGF-β is a signaling pathway that is involved in cell growth, differentiation, and apoptosis, while NF-kappa-B is a signaling pathway that is involved in inflammation and immune responses.

MIR127 has also been shown to play a role in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. MIR127 has been shown to play a role in the regulation of cell adhesion by activating the tight-binding protein E-cadherin. E-cadherin is a transmembrane protein that is involved in cell adhesion and has been shown to play a role in the regulation of various diseases, including cancer.

In addition to its involvement in cellular processes, MIR127 has also been shown to play a role in the regulation of gene expression. MIR127 has been shown to interact with several proteins, including the transcription factor NF-kappa-B. This interaction between MIR127 and NF-kappa-B has been shown to play a role in the regulation of gene expression, including the regulation of cancer cell growth and survival.

MIR127 has also been shown to have potential as a biomarker for various diseases, including cancer. For example, MIR127 has been shown to be downregulated in various types of cancer, including breast, lung, and ovarian cancer. This downregulation of MIR127 has been shown to play a role in the regulation of cancer cell survival and growth.

In conclusion, MIR127 is a non-coding RNA molecule that has been shown to play a critical role in regulating gene expression and cellular processes in various organisms. Its involvement in the regulation of cell apoptosis, signaling pathways, and adhesion, as well as its potential as a biomarker for cancer, make MIR127 an attractive target for drug development. Further research is needed to fully understand the role of MIR127 in

Protein Name: MicroRNA 127

The "MIR127 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR127 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1